Pharmaforce Reports Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth -14.68%
- Profit Growth 9.14%
- Ebitda 165.65%
- Net Worth 53.79%
- Total Assets 20.60%
About Pharmaforce Reports
Pharmaforce Reports Private Limited (PRPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 02 May 2013 and has a history of 11 years and nine months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Llena Samant, Tom Nordhoy, Asit Sharma, and One other member serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74900PN2013FTC147209
- Company No.
147209
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
02 May 2013
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Pharma
Who are the key members and board of directors at Pharmaforce Reports?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Llena Samant  | Director | 02-May-2013 | Current |
| Tom Nordhoy | Director | 02-May-2013 | Current |
Asit Sharma  | Director | 18-Apr-2019 | Current |
| Snehal Patil | Additional Director | 26-Apr-2021 | Current |
Financial Performance of Pharmaforce Reports.
Pharmaforce Reports Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 14.68% decrease. The company also saw a slight improvement in profitability, with a 9.14% increase in profit. The company's net worth Soared by an impressive increase of 53.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmaforce Reports?
In 2019, Pharmaforce Reports had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eastin Tech LlpAsit Sharma is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmaforce Reports?
Unlock and access historical data on people associated with Pharmaforce Reports, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmaforce Reports, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmaforce Reports's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
